PDS Planning Inc Sells 1,659 Shares of Bristol-Myers Squibb (NYSE:BMY)

PDS Planning Inc lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 20.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,560 shares of the biopharmaceutical company’s stock after selling 1,659 shares during the period. PDS Planning Inc’s holdings in Bristol-Myers Squibb were worth $337,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. RFG Advisory LLC increased its stake in shares of Bristol-Myers Squibb by 13.7% in the 3rd quarter. RFG Advisory LLC now owns 16,952 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 2,046 shares in the last quarter. Onyx Bridge Wealth Group LLC increased its stake in shares of Bristol-Myers Squibb by 25.3% in the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 7,226 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 1,457 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 58.3% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,967 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 1,830 shares in the last quarter. BTC Capital Management Inc. increased its stake in shares of Bristol-Myers Squibb by 7.9% in the 3rd quarter. BTC Capital Management Inc. now owns 92,514 shares of the biopharmaceutical company’s stock valued at $5,370,000 after acquiring an additional 6,746 shares in the last quarter. Finally, Advisors Management Group Inc. ADV increased its stake in shares of Bristol-Myers Squibb by 19.9% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 7,717 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 1,281 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.1 %

Shares of Bristol-Myers Squibb stock traded up $0.04 on Tuesday, hitting $49.18. The stock had a trading volume of 2,343,238 shares, compared to its average volume of 15,436,951. The stock’s 50-day simple moving average is $51.22 and its two-hundred day simple moving average is $51.38. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The stock has a market cap of $99.68 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.48 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same quarter last year, the firm posted $1.82 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.88%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.